Maruishi Pharmaceutical Japanese Site

About Maruishi

About Maruishi
Corporate Officers
Corporate Organization
Pharmaceutical Research and Development Division
Production Division
Pharmaceutical Division
Product Alliances
Quality, Safety and Regulatory Affairs Management Division
Our Products
Financial Highlights


Clinical Development Division
Dedicates all sorts of R&D activities not only conducting from basic drug research to preclinical and clinical (Phase I-IV)
studies but also proposing product life cycle management.

Discovery Research Department evaluates candidate compounds for development, screens pharmacological actions, elucidates their mechanism of actions, and searches for new seeds. It also carries out synthetic researches for optimization of drug formulations as well as for the study of metabolite and degradation products.
Pharmaceutical Research Department mainly conducts CMC and preclinical studies in preparation for PMDA submissions, aiming to bring the candidate pharmaceutical products quickly to the market. It carries out physicochemical studies, stability testing, and establishes test procedures and acceptance criteria for CMC development. Concurrently, it conducts pharmacokinetics and safety studies for preclinical development. In addition, it evaluates efficacy of various disinfectants using microorganisms to help improve the products for infection control.
Department of Project Management and Research Planning serves as a liaison between related departments and divisions. Their jobs are management of ongoing R&D projects, information search around the R&D themes and other general management.
These three departments establishes and maintains infrastructure that conforms to standards such as Good Laboratory Practice (GLP) and quality. Furthermore, animal welfare is always taken into consideration when conducting animal studies. Each department strives for more effective and safer pharmaceutical drug development to contribute to maintaining healthy lives of people.
Clinical Development Department conducts clinical trials of the new drug candidates whose efficacy and safety were confirmed in non-clinical studies, under Good Clinical Practice (GCP)- from phase I to phase III studies - to confirm their efficacy and safety in human. Then, it obtains manufacturing and marketing approval of new drugs.

(c)2006 Maruishi Pharmaceutical. Co., Ltd. All rights reserved.